<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Terapevticheskii arkhiv</journal-id><journal-title-group><journal-title xml:lang="en">Terapevticheskii arkhiv</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапевтический архив</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0040-3660</issn><issn publication-format="electronic">2309-5342</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">31430</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Editorial article</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Передовая статья</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Value of adhesion molecules for evaluating the efficiency of therapy for ulcerative colitis and Crohn's disease</article-title><trans-title-group xml:lang="ru"><trans-title>Значение молекул адгезии для оценки эффективности терапии язвенного колита и болезни Крона</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Parfenov</surname><given-names>A I</given-names></name><name xml:lang="ru"><surname>Парфенов</surname><given-names>А И</given-names></name></name-alternatives><email>asfold@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Boldyreva</surname><given-names>O N</given-names></name><name xml:lang="ru"><surname>Болдырева</surname><given-names>О Н</given-names></name></name-alternatives><email>galaopagos@inbox.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ruchkina</surname><given-names>I N</given-names></name><name xml:lang="ru"><surname>Ручкина</surname><given-names>И Н</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kniazev</surname><given-names>O V</given-names></name><name xml:lang="ru"><surname>Князев</surname><given-names>О В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Sagynbaeva</surname><given-names>V É</given-names></name><name xml:lang="ru"><surname>Сагынбаева</surname><given-names>В Э</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Shcherbakov</surname><given-names>P L</given-names></name><name xml:lang="ru"><surname>Щербаков</surname><given-names>П Л</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Khomeriki</surname><given-names>S G</given-names></name><name xml:lang="ru"><surname>Хомерики</surname><given-names>С Г</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Lazebnik</surname><given-names>L B</given-names></name><name xml:lang="ru"><surname>Лазебник</surname><given-names>Л Б</given-names></name></name-alternatives><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Konopliannikov</surname><given-names>A G</given-names></name><name xml:lang="ru"><surname>Коноплянников</surname><given-names>А Г</given-names></name></name-alternatives><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">Московский клинический научно-практический центр. ЦНИИ гастроэнтерологии Департамента здравоохранения Москвы</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">Московский государственный медико-стоматологический университет им. А.И. Евдокимова Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">Медицинский радиологический научный центр Минздрава России, Обнинск</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2014-02-15" publication-format="electronic"><day>15</day><month>02</month><year>2014</year></pub-date><volume>86</volume><issue>2</issue><issue-title xml:lang="en">VOL 86, NO2 ()</issue-title><issue-title xml:lang="ru">ТОМ 86, №2 (2014)</issue-title><fpage>32</fpage><lpage>38</lpage><history><date date-type="received" iso-8601-date="2020-04-10"><day>10</day><month>04</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2014, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2014, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2014</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ter-arkhiv.ru/0040-3660/article/view/31430">https://ter-arkhiv.ru/0040-3660/article/view/31430</self-uri><abstract xml:lang="en"><p>AIM: To define the value of adhesion molecules (sVCAM-1 integrin, P-selectin, E-selectin, and L-selectin) for the prediction and evaluation of the efficiency of treatment in patients with ulcerative colitis (UC) and Crohn's disease/MATERIAL AND METHODS: Twenty-six patients with UC and 14 patients with CD were examined. Of them, 16 patients took infliximab (INF) in a dose of 5 mg/kg of body weight according to the standard scheme; 14 patients received cultured mesenchymal stem stromal cells (MSSCs) in a quantity of 150·108 cells, and 10 had azathioprine (AZA) 2 mg/kg and glucocorticosteroids (GCS) 1 mg/kg of body weight. Enzyme immunoassay was used to determine the serum concentration of the adhesion molecules (L-selectin, E-selectin, P-selectin, and sVCAM-1 integrin) before and 2 months after treatment/RESULTS: The signs of bowel inflammatory disease activity and the elevated levels of adhesion molecules whose synthesis did not occur under normal conditions remained in the patients receiving GCS and AZA. INF treatment caused a decrease in P-selectin, E-selectin, and sVCAM-1 levels to 8.9±1.0, 5.5±1.7, and 9.5±4.4 ng/ml, respectively (p&lt;0.001). Incorporation of MSSCs was followed by a reduction of the concentrations of P-selectin and E-selectin to 6.9±1.1 and 5.7±1.3 ng/ml, respectively (р&lt;0.001). The level of integrin (cVCAM-1) fell to 12.2±2.2 ng/ml (p&gt;0.1); that of L-selectin did not drop after MSSC administration and INF induction therapy/CONCLUSION: P-selectin, E-selectin, L-selectin, and sVCAM-1 integrin are current inflammatory markers and may be used to evaluate the efficiency of standard and biological therapies for inflammatory bowel diseases and to predict disease course.</p></abstract><trans-abstract xml:lang="ru"><p>Резюме. Цель исследования. Определить значение молекул адгезии интегрина sVCAM-1 и селектинов P, E и L для прогноза и оценки эффективности лечения больных язвенным колитом (ЯК) и болезнью Крона (БК). Материалы и методы. Обследовали 26 больных ЯК и 14 больных БК, из них 16 получали инфликсимаб (ИНФ) в дозе 5 мг/кг массы тела по стандартной схеме, 14 - культуру мезенхимальных стволовых стромальных клеток (МССК) в количестве 150·108, 10 - азатиоприн (АЗА) в дозе 2 мг/кг и кортикостероиды (ГКС) в дозе 1 мг/кг массы тела. В сыворотке крови определяли концентрацию молекул адгезии (селектинов L, Е и Р, интегрина sVCAM-1) иммуноферментным методом до начала лечения и через 2 мес после него. Результаты. У больных, получавших ГКС и АЗА, сохранялись признаки активности воспалительного заболевания кишечника и повышенные уровни молекул адгезии, синтез которых в нормальных условиях не происходит. Лечение ИНФ вызывало снижение уровней P-селектина, E-селектина, sVCAM-1 до 8,9±1,0, 5,5±1,7 и 9,5±4,4 нг/мл соответственно (р&lt;0,001). Введение МССК сопровождалось снижением уровней Р-селектина, Е-селектина до 6,9±1,1 и 5,7±1,3 нг/мл соответственно (р&lt;0,001). Уровень интегрина (sVCAM-1) снизился до 12,2±2,2 нг/мл (р&gt;0,1), уровень L-селектина после введения МССК и индукционной терапии ИНФ не снижался. Заключение. Селектины P, E и L, а также интегрин sVCAM-1 являются современными маркерами воспаления и могут быть использованы для оценки эффективности стандартной и биологической терапии при воспалительных заболеваниях кишечника и прогнозирования течения заболевания.</p></trans-abstract><kwd-group xml:lang="en"><kwd>inflammatory bowel diseases</kwd><kwd>Crohn's disease</kwd><kwd>ulcerative colitis</kwd><kwd>azathioprine</kwd><kwd>glucocorticosteroids</kwd><kwd>infliximab</kwd><kwd>mesenchymal stromal cells</kwd><kwd>P-selectin</kwd><kwd>E-selectin</kwd><kwd>L-selectin</kwd><kwd>and sVCAM-1 integrin</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>воспалительные заболевания кишечника</kwd><kwd>болезнь Крона</kwd><kwd>язвенный колит</kwd><kwd>азатиоприн</kwd><kwd>глюкокортикостероиды</kwd><kwd>инфликсимаб</kwd><kwd>мезенхимальные стромальные клетки</kwd><kwd>P-селектин</kwd><kwd>E-селектин</kwd><kwd>L-селектин</kwd><kwd>интегрин sVCAM-1</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Bevilacqua M. Endothelial cell-leukocyte adhesion molecules. Annu Rev Immunol 2001; 11: 767-773.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Parker D. T cell-dependent B cell activation. Annu Rev Immunol 1993; 11: 331-360.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Ройт А., Бростофф Дж., Мейл Д. Иммунология. М 2000: 169-175.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Barczyk M., Carracedo S., Gullberg D. Integrins. Cell Tissue Res 2010; 1: 269-280.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Berman A.E., Kozlova N.I. Integrins: structure and functions. Membr Cell Biol 2000; 13: 207-244.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Cybulsky M.I., Liyama K., Li H. et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 2001; 107: 1255-1262.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Vitte J., Benoliel A.M., Eymeric P. et al. Beta-1 Integrin-mediated adhesion may be initiated by multiple incomplete bonds, thus accounting for the functional importance of receptor clustering. J Biophys 2004; 86: 4059-4074.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Borsig L., Wong R., Hynes R.O. et al. Synergistic effects of L-and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. PNAS 2002; 99: 2193-2198.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Румянцев В.Г. Язвенный колит. Руководство для врачей. М: МИА 2009; 424.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Szántó S., Gál I., Gonda A. et al. Expression of L-Selectin, but Not CD44, is required for early neutrophil extravasation in antigen-induced arthritis. J Immunol 2004; 172: 6723-6734.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Arao S., Masumoto A., Otsuki M. Beta 1 integrins play an essential role in adhesion and invasion of pancreatic carcinoma cells. Pancreas 2000; 20: 129-137.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Goggins M.G., Goh J., O'Connell M.A. et al. Soluble adhesion molecules in inflammatory bowel disease. Ir J Med Sci 2001; 179: 107-111.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Wakelkamp I.M., Gerding M.N., van der Meer J.W. et al. Smoking and disease severity are independent determinants of serum adhesion molecule levels in Graves' ophthalmopathy. Clin Exp Immunol 2002; 2: 316-320.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Kaplanski G., Bongvand P. Cytokines and Chemokines. Cell Mol Biol 2001; 47: 569-574.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Гусев Д.Е., Пальцева Е.М., Потиевский Б.Г. и др. Кардиология и сердечно-сосудистая хирургия. М: Медиа Сфера 2009; 2: 11-14.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Павленко В.В., Амирханова Л.З., Катаганова Г.А. и др. Растворимые молекулы адгезии (ICAM-1, ICAM-2 и L-селектин) при язвенном колите. Мед вестн Северного Кавказа 2012; 1: 4-6.</mixed-citation></ref></ref-list></back></article>
